Cabergoline

Cabergoline is a potent and selective dopamine D2 receptor agonist (Kis = 0.912 and 6,935 nM for D2 and D1 receptors, respectively, in rat striatum) that inhibits the secretion of prolactin (PRL) and growth hormone. It inhibits PRL secretion in and growth of rat pituitary tumor cells in a concentration-dependent manner, an effect which can be reversed by the dopamine D2 receptor antagonist haloperidol (Cay-12014). Cabergoline suppresses the mammalian target of rapamycin (mTOR) signaling pathway in a time-dependent manner and induces autophagy and cell death in MMQ and GH3 rat pituitary cells. In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a monkey model of Parkinson's disease induced by MPTP. Formulations containing cabergoline have been used to treat prolactinomas.Formal Name: N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-ergoline-8beta-carboxamide. CAS Number: 81409-90-7. Synonyms: FCE 21336. Molecular Formula: C26H37N5O2. Formula Weight: 451.6. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: Chloroform: Slightly Soluble, Methanol: Slightly Soluble. SMILES: O=C(NCC)N(CCCN(C)C)C([C@H]1CN(CC=C)[C@@]2([H])[C@](C3=C4C(C2)=CNC4=CC=C3)([H])C1)=O. InChi Code: InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1. InChi Key: KORNTPPJEAJQIU-KJXAQDMKSA-N.